Disease Extent at Secondary Cytoreductive Surgery is Predictive of Progression-free and Overall Survival in Advanced Stage Ovarian Cancer: an NRG Oncology/Gynecologic Oncology Group study

PURPOSE: GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evalua...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Gynecol Oncol
Main Authors: Rose, Peter G., Java, James J., Morgan, Mark A., Secord, Angeles Alvarez, Kesterson, Joshua P., Stehman, Frederick B., Warshal, David P., Creasman, William T., Hanjani, Parviz, Morris, Robert T., Copeland, Larry J.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5720165/
https://ncbi.nlm.nih.gov/pubmed/27692669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.09.005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares